VVP
AZN icon

Vulcan Value Partners’s AstraZeneca AZN Stock Holding History

Vulcan Value Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,125
Closed -$212K – 57
2015
Q4 		$212K Buy
+3,125
New +$205K ﹤0.01% 60

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vulcan Value Partners's AZN Position: Q1 2016 in Review

Vulcan Value Partners sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 3,125 shares — an estimated $212K sold.

Vulcan Value Partners first reported a position in AZN in Q4 2015 and held it in 1 quarter. The position peaked at $212K in Q4 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

  • Vulcan Value Partners reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
  • Vulcan Value Partners sold 3,125 AstraZeneca shares in Q1 2016, an estimated $212K.
  • Vulcan Value Partners first reported a position in AstraZeneca in Q4 2015 and held it in 1 quarter.
  • Vulcan Value Partners's AstraZeneca position peaked at $212K in Q4 2015.
  • 390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Vulcan Value Partners's 13F filing for Q1 2016, filed 18 May 2016.